Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 515-519

  Agarwal, Shilpi ^a   Misra, Ramnath ^a   Aggarwal, Amita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokines; Inflammation; Juvenile rheumatoid arthritis; TH17 cells

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CULTURE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBROBLAST; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIOCYTE;

ADOLESCENT; ADULT; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; SYNOVIAL FLUID;

EID: 40649083317     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sullivan KE. Inflammation in juvenile idiopathic arthritis. Pediatr Clin North Am 2005;52:335-57.
2. Gottorno M, Gerloni V, Morando A, et al. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor-1 in juvenile idiopathic arthritides. J Rheumatol 2002;29:1774-9.
3. Gottorno M, Vignola S, Falcini F, et al. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002;29:826-31.
4. Peake NJ, Cawston TE, Rowan AD, et al. Levels of matrix metalloproteinase MMP1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology Oxford 2005;44:1383-9.
5. MacNaul KL, Chartain N, Larks M, et al. Discordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. J Biol Chem 1990;265:17238-45.
6. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector of CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88.
7. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-603.
8. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003;48:594-601.
9. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cells subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82.
10. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluid from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
11. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
12. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7.
13. Lubberts E, Konders MI, Oppers-Walgreen B, et al. Treatment with a neutalizing anti-murine IL-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction and bone erosion. Arthritis Rheum 2004;50:650-9.
14. de Jager W, Hoppenrejis EPAH, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross sectional study. Ann Rheum Dis 2007;66:589-98.
15. Aggarwal A, Agarwal V, Danda D, Misra R. Outcome in juvenile rheumatoid arthritis in India. Indian Pediatrics 2004;41:180-4.
16. Petty RE, South wood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis; Durban, 1997. J Rheumatol 1998;25:1991-4.
17. Stebulis JA, Rossetti RA, Atez FJ, Zurier RB. Fibroblast like synovial cells derived from synovial fluid. J Rheumatol 2005;32:301-6.
18. Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
19. Saxena N, Aggarwal A, Misra R. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol 2005;32:1349-53.
20. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000;12:1092-9.
21. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. IL-17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13.
22. Konders MI, Kolls JK, Oppers-Walgreen B, et al. IL-17 receptor deficiency results in impaired synovial expression of IL1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated Streptococcal cell wall induced arthritis. Arthritis Rheum 2005;52:3239-47.